> A group of investors have agreed to buy $30 million of Sequenom stock. The money will be used as working capital for Sequenom, which makes biotech research equipment. Report
> Inspire Pharmaceuticals met with the FDA to discuss its approvable letter for its dry eye clinical program for diquafosol. Release
> Optimer Pharmaceuticals has launched Phase III trials of OPT-99 for bacterial gastroenteritis. Release
> YM BioSciences says its partner, Oncoscience, has been cleared by German regulators to initiate a Phase III trial of nimotuzumab in combination with radiation in children with inoperable pontine (brain stem) glioma. Release
> BioFocus, a unit of Galapagos, has inked a deal to supply chemical compounds to Roche for the next three years. Report
> Immunicon has extended its R&D agreement with Pfizer for detecting antigens on tumor cells. Release
> BG Medicine will conduct a joint biomarker program for muscle toxicity with Mitsubishi Pharma. Release
> The FDA has added six months of market exclusivity to Cephalon's Provigil. Release
And Finally… British doctor Jeremy Farrar has more first hand experience dealing with bird flu cases than anyone else, and he believes fears of a pandemic are at least somewhat overblown. Article